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Abstract: Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus replication. 
In HBeAg-positive and HBeAg-negative lamivudine-naïve patients with chronic hepatitis B 
(CHB), treatment with ETV at a dose of 0.5 mg daily is associated with a more potent viral 
suppression, a higher rate of biochemical remission and a greater improvement of liver histology 
compared to Lamivudine (LAM). After 3 years of ETV treatment, the majority of patients (94%) 
may achieve serum HBV DNA levels undetectable by sensitive PCR assays. ETV treatment of 
patients with LAM-resistant HBV mutants requires a higher daily dose of 1 mg yet, potent HBV 
suppression at 3 years is achieved only in 40% of them while the cumulative rate of genotypic 
HBV resistance increases from 6% in the ﬁ  rst year to  30% in year 3. ETV resistance of HBV 
is rare in lamivudine-naïve patients with a reported rate of  1% after three years of treatment. In 
conclusion, ETV is a very potent anti-HBV drug with a high genetic barrier to resistance, highly 
effective in lamivudine-naïve CHB patients and most promising for their long-term treatment 
but not very suitable for CHB patients harboring LAM–resistant HBV mutants.
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Introduction
Chronic hepatitis B virus (HBV) infection is a major health problem, affecting 
hundreds of millions of people worldwide. It may progress to cirrhosis and hepato-
cellular carcinoma (HCC) and is responsible for almost 1 million deaths annually 
(Lee 1997; Maddrey 2000). Eradication of HBV infection with currently available 
therapies is not really possible. Resolution of the infection, as indicated by HBsAg loss 
and development of anti-HBs, is also extremely rare. Thus, the most realistic goal of 
hitherto approved therapies for chronic hepatitis B (CHB) is potent and durable sup-
pression of viral replication aiming at stop of progression and remission/regression of 
the underlying liver disease (Di Marco et al 2004; Liaw et al 2004). More speciﬁ  cally, 
in patients with HBeAg-positive CHB the end point and goal of treatment is HBeAg 
seroconversion, while in patients with HBeAg-negative CHB is durable suppression of 
HBV to HBV DNA levels undetectable by real time PCR assays (Lok et al 2001).
Six drugs have been approved for the treatment of chronic hepatitis B, standard 
interferon-α (IFN-α), the Pegylated form (PEG)-IFN-α-2a, and the nucleos(t)ide 
analogues Lamivudine (LAM), Adefovir Dipivoxil (ADV), Entecavir (ETV) and most 
recently Telbivudine (LdT).
Interferon-alpha
Interferon-alpha is the ﬁ  rst drug approved for the treatment of CHB. In HBeAg-
positive CHB ﬁ  nite course of treatment with standard IFN-α has achieved HBeAg 
loss in 33% of treated patients vs 12% of placebo-treated controls, p = 0.0001 
(Wong et al 1993), with responses being durable after stopping treatment (Nie-
deraou et al 1996). In HBeAg-negative CHB, long-term biochemical remission Therapeutics and Clinical Risk Management 2007:3(6) 1078
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has been reported in 15%–25% of patients treated for 6 or 
more months with a signiﬁ  cant percentage of them (31.6%) 
also loosing HBsAg (Hadziyannis et al 1990; Manesis and 
Hadziyannis 2001; Papatheodoridis et al 2001). On the 
other hand PEG-IFN-α-2a either alone or in combination 
with LAM in HBeAg-positive CHB, achieved similar rates 
of HBeAg seroconversion in 32% and 27% of patients, 
respectively and both regimens were superior to LAM 
monotherapy (32% vs 19%, p   0.001 and 27% vs 19%, 
p = 0.02) (Lau et al 2005) (see also Figure 1). In HBeAg-
negative CHB, PEG-IFN-α-2a alone or in combination 
with LAM achieved similar rates of virologic remission 
(HBV-DNA   20.000 cp/mL) in 43% and 44% of patients, 
respectively and again the two regimens were clearly supe-
rior to LAM monotherapy (29%, p = 0.007 and p = 0.003, 
respectively) (Marcellin et al 2004). Furthermore, follow-up 
of patients, 2 years after discontinuation of treatment has 
shown that the response appears to be durable (Marcellin 
et al 2006). Treatment with PEG-IFN-α-2a is probably 
superior to standard IFN-α, but there is no comparative 
study between the two forms of interferon-α applied in 
courses of the same duration. Although treatment with 
IFN-αs has many adverse events and the disadvantage of 
subcutaneous administration, these are the only available 
drugs that can achieve HBsAg seroconversion in ﬁ  nite 
courses of treatment of less than one year duration (Wong 
et al 1993; Marcellin et al 2004; Lau et al 2005).
In view of the above data it is clear that both in HBeAg-
positive and HBeAg-negative patients with chronic hepatitis B 
pegylated IFN-α2a monotherapy in ﬁ  nite courses of 48 weeks 
duration, achieves higher rates of responses sustained after 
their discontinuation compared to LAM monotherapy.
Lamivudine
Lamivudine, the ﬁ  rst licensed nucleoside analogue (Lai et al 
1998; Dienstang et al 1999), may achieve HBeAg seroconver-
sion, in 18% of HBeAg-positive CHB patients at the ﬁ  rst year 
and in 27% and 40% at the second and third year respectively 
(Lai et al 1998; Dienstang et al 1999; Liaw et al 2000; Leung 
et al 2001). In HBeAg-negative CHB, LAM therapy for one 
year resulted in undetectable serum HBV DNA in 65% of 
patients (Tassopoulos et al 1999). The high rate of virologic 
response at one year is not sustainable after discontinuation 
of therapy, while prolongation of treatment is associated with 
decreasing rates of virologic response due to the emergence 
of LAM-resistant HBV mutants in progressively increasing 
rates reaching levels above 60% in 4 to 5 years time (Lai et al 
1998; Dienstang et al 1999; Liaw et al 2000; Leung et al 2001; 
Papatheodoridis et al 2002; Lok et al 2003). The develop-
ment of viral resistance may be associated with worsening of 
liver histology, exacerbation of liver disease and even with 
liver failure and deaths especially in patients with cirrhosis 
(Dienstag et al 2003; Lok et al 2003; Di Marco et al 2004; 
Liaw et al 2004; Papatheodoridis et al 2005).
Adefovir dipivoxil 
Adefovir dipivoxil, a nucleotide analogue, the second 
licensed oral anti-HBV agent, is effective in the treatment 
of both wild type and LAM-resistant HBV (Hadziyannis 
et al 2003; Marcellin et al 2003; Peters et al 2004). 
Figure 1 Comparison of responses to treatment (HBeAg seroconversion and log reduction of serum HBV DNA) of HBeAg positive chronic hepatitis B.
Lau et al. 2005. N Engl J Med, 352:2682–95. Dienstag et al. 1999. N Engl J Med, 341:1256–63. Marcellin et al. 2005. EASL,   Abstract 73. Lai et al. 2005. AASLD, Abstract 
72404.(LB1) Chang et al. 2004  AASLD, Abstract 70. Telbivudine package insert. Marcellin et al. 2003. N Engl J Med. 348:808–16. Chang et al. 2006. N Engl J Med. 354:1001–10.
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In HBeAg-positive CHB, HBeAg seroconversion was 
achieved in 12% of patients at the ﬁ  rst year, increasing 
to 29% and 43% at the second and third year of therapy 
respectively (Marcellin et al 2003, 2005). In HBeAg-
negative CHB, long-term ADV therapy is associated with 
undetectable serum HBV DNA in 71%, 79%, 65% and 67% 
at year 2, 3, 4 and 5, respectively (Hadziyannis et al 2003, 
2005a, 2005b, 2006). ADV resistance is delayed and infre-
quent developing after the ﬁ  rst year of treatment. Genotypic 
HBV resistance may emerge in 3%, 11%, 18% and 29% 
of patients at years 2, 3, 4 and 5 of treatment, respectively 
(Hadziyannis et al 2003, 2005a, 2005b, 2006). However, 
virologic and biochemical breakthroughs at year 5 are 
restricted only to 16% and 11% respectively (Hadziyannis 
et al 2006). In patients with LAM-resistant HBV strains, 
treatment with ADV alone or in combination with LAM 
has similar rate of virological (26% vs 35%) and biochemi-
cal response (47% vs 53%) at one year (Peters et al 2004). 
However, longer duration of treatment has shown that 
adding adefovir on lamivudine rather than switching from 
lamivudine to adefovir represents the treatment of choice in 
patients developing LAM-resistant HBV mutants (Fung et al 
2005, 2006; Lampertico et al 2006; Rapti et al 2007).
Telbivudine
Telbivudine (LdT, β-L-2'-deoxythimidine, Idenix, Cambridge, 
MA) is an L nucleoside analogue of thymidine, approved by 
FDA on late 2006 for the treatment of chronic hepatitis B 
under the trade name of Tyzeka at a daily dose of 600 mg. 
It is a reverse transcriptase inhibitor and acts by competing 
with the natural substrate thymidine 5' triphosphate and 
its incorporation into viral DNA causes chain termination, 
resulting in inhibition of HBV replication. It is a potent 
anti-HBV agent inhibiting the synthesis both of the ﬁ  rst and 
the second DNA strand of the virus and in phase II studies 
it has been found to be more effective than lamivudine. In 
HBeAg-positive patients it achieved a greater reduction in 
HBV DNA levels (6.01 log10 vs 4.57 log10, p   0.05) as well 
as higher rates of HBV DNA undetectability (61% vs 32%, 
p   0.05) and normalization of ALT levels (86% vs 63%, 
p   0.05) (Lai et al 2004; Lai et al 2005a). The year 1 and 2 
results of a very large registration trial in 1367 individuals 
with HBeAg-positive and -negative CHB, the GLOBE trial, 
have been reported in the 2005 AASLD (Lai et al 2005b) and 
the 2006 EASL (Thongsawat et al 2006) and AASLD (Lai 
et al 2006a) Meetings. The following important observations 
came out from the analyses of the results at weeks 52 and 
104 of this pivotal LdT study:
1.  LdT is equally safe but more effective than lamivudine 
in terms of absolute HBV DNA reduction from baseline 
(HBeAg-positive: 6.5 log10 vs 5.5 log10 at week 52, 
p   0.05 and 5.7 log10 vs 4.4 log10, p   0.05, at week 
104, respectively, HBeAg-negative: 5.2 log10 vs 4.4 
log10, p   0.05 at week 52 and 5 log10 vs 4.2 log10, 
p   0.05 at week 104, respectively) and time of undetect-
ability. However there is no signiﬁ  cant difference from 
LAM in HBeAg loss and seroconversion to anti-HBe 
(26% vs 23% at week 52, 35% vs 29% at week 104 
and 22% vs 21% at week 52, 30% vs 25% at week 104, 
respectively) (Lai et al 2006b).
2.  Treatment failures and HBV resistance are less frequent 
with LdT compared to LAM (treatment failure in HBeAg- 
negative patients 0.9% vs 7.6%, p   0.001 and in HBeAg-
positive 6.8% vs 18.8%, p   0.001, respectively) (Lai 
et al 2006b).
3.  Both in LdT and LAM treated HBeAg-positive patients, 
the rates of HBeAg seroconversion are signiﬁ  cantly 
increased if a profound and rapid HBV suppression 
to undetectability of serum HBV DNA at week 24 is 
achieved, this effect being also associated with enhanced 
T-cell reactivity to HBc protein (Cooksley et al 2006).
Entecavir
Entecavir, a novel carbocyclic analog of 2' deoxyguanosine 
(Figure 2), has been approved in 2005 in USA and in 2006 in 
Europe for naïve and lamivudine-resistant chronic hepatitis 
B treatment. Data on its safety, side effects, short- and long-
term efﬁ  cacy and HBV resistance in the various subsets of 
HBV patients are critically reviewed in this article.
In Figure 1 the HBeAg response rates achieved with 
one year of therapy by ETV , the other three approved 
nucleos(t)ides and pegylated interferon-alfa2a together with 
their potency in terms of log reduction in HBV DNA levels 
are shown in a comparative way.
Entecavir in chronic hepatitis B
Entecavir therapy in treatment-naïve 
patients with chronic hepatitis B
The safety and efﬁ  cacy of ETV were initially evaluated in 
a randomized, placebo-controlled, dose-escalating study 
(De Man et al 2001). In patients with CHB, ETV was admin-
istered at doses of 0.05 mg, 0.1 mg, 0.5 mg and 1 mg and 
compared to placebo for 28 days (De Man et al 2001). All 
patients were followed-up 24 weeks off therapy. All doses of 
ETV were well tolerated and were associated with a signiﬁ  -
cant decline in serum HBV DNA levels. However, a slower Therapeutics and Clinical Risk Management 2007:3(6) 1080
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rebound of viremia in the post treatment follow-up period 
was observed with the 0.5 and 1 mg of ETV compared with 
the other two lower doses (p   0.05) (De Man et al 2001). 
During the post-treatment period, 9% of ETV treated patients 
experienced hepatic ﬂ  ares deﬁ  ned as elevation in ALT greater 
than twice the baseline level and more than 10 times the upper 
limit of normal. None of these ﬂ  ares were associated with 
elevated bilirubin levels and were not clinically signiﬁ  cant. 
This study has showed that ETV is a potent inhibitor of 
HBV in humans, but longer duration dosing trials should 
be performed before deﬁ  nite conclusions about the safety 
and the role of ETV in the treatment of chronic hepatitis B 
infection are made.
In another double-blind randomized study, the safety and 
efﬁ  cacy of 3 doses of ETV were evaluated and compared 
to LAM in patients with CHB (Lai et al 2002). Entecavir 
doses of 0.01 mg, 0.1 mg, 0.5 mg and LAM 100 mg daily 
were administered for 24 weeks. Complete response was 
deﬁ  ned as undetectable serum HBV DNA by bDNA (cut-off 
0.7 Meq/mL) at week 22, with normal ALT and undetectable 
HBeAg for HBeAg-positive patient at baseline. Treatment 
was discontinuated in individuals with complete response and 
they were followed-up for 12 weeks. Partial response was 
deﬁ  ned as undetectable serum HBV DNA by bDNA assay 
at week 22, but without loss of HBeAg for HBeAg-positive 
patients or with elevated ALT for HBeAg-negative patients 
at baseline. In these patients, LAM 100 mg were given for 
48 weeks. The nonresponders (detectable HBV DNA by 
bDNA) were managed after week 24 by their physician and 
followed-up for 12 weeks. One hundred sixty-nine patients 
(81% HBeAg-positive) completed 24 weeks of treatment 
period. At the end of therapy a signiﬁ  cantly higher proportion 
(83.7%) of patients receiving 0.5 mg of ETV had undetectable 
HBV DNA levels (bDNA   0.7Meq/mL) compared to LAM 
100 mg (57.5%, p = 0.008), while the response to the ETV 
0.1 mg dose was similar with LAM (61.8% vs 57.5%). Serum 
HBV DNA undetectable by the b-DNA assay and ALT 
normalization were observed in 23.1% and 50%, 61.8% and 
83.3%, 83.7% and 69%, 57.5% and 59.1% at the 0.01, 0.1, 
0.5 mg ETV and the 100 mg LAM, doses respectively (Lai 
et al 2002). Complete or partial response occurred in 23%, 
62%, 84% and 57% of patients in the 0.01 mg, 0.1 mg and 
0.5 mg ETV and LAM group, respectively. After discontinu-
ation of treatment, ALT elevation   3xULN was observed 
in 21% of patients in the 0.01 mg ETV group compared to 
10.5% in the LAM group and in 3% and 4.5% in the 0.1 and 
0.5 mg ETV groups respectively. On the basis of the results 
of this study it was considered that the optimal dose of ETV 
for the treatment of naïve patients should be 0.5 mg daily 
(Lai et al 2002).
Efﬁ  cacy in HBe-positive patients
In a randomized phase III double-blind trial, 715 treatment-
naïve, HBeAg-positive (+) CHB patients were assigned to 
receive either 0.5 mg of ETV or 100 mg of LAM once daily for 
a minimum period of 52 weeks (Chang et al 2006a). Accord-
ing to the study protocol clinical-management decisions were 
made at week 52 on the basis of the results of HBV DNA lev-
els (b-DNA) and HBeAg assays on serum samples obtained 
at week 48. Patients who had a complete response deﬁ  ned as 
undetectable serum HBV DNA levels (  0.7 Meq/mL) and 
HBeAg loss and the nonresponders deﬁ  ned by serum HBV 
DNA levels   0.7 Meq/mL discontinued treatment at week 
52. Patients who achieved only virologic response [unde-
tectable serum HBV DNA levels ( 0.7 Meq/mL), without 
HBeAg loss] were continued on therapy up to 96 weeks 
CH2
Figure 2 The chemical structure of entecavir.Therapeutics and Clinical Risk Management 2007:3(6) 1081
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Table 1 Comparison of entecavir vs lamivudine in HBeAg positive and HBeAg-negative treatment-naïve patients with chronic 
hepatitis B (CHB)
 HBeAg  (+) CHB      HBeAg (−) CHB
  LAM   ETV   LAM   ETV
  Year 1  Year 2  Year 1  Year 2  Year 1  Year 2  Year 1  Year 2
Undetectable  36%  39% 67%  80% 72% 77% 90%  94%
HBV DNA
ALT  normal  60%  77% 68%  84% 71% 84% 78%  89%
HBeAg  loss  20% 28%  22% 32%  NA  NA  NA  NA
HBeAg  seroconversion  18% 25%  21% 31%  NA  NA  NA  NA
Histologic  improvement  62%  NA 72%  NA 61%  NA 70%  NA
HBV  resistance  13%  NA 0% 0%  6% NA 0% 0%
Abbreviations: CHB, chronic hepatitis B; ETV, entecavir; LAM, lamivudine; ALT, alanine aminotransferase; HBV, hepatitis B virus; NA, non applicable; vs, versus.
(Gish et al 2005; Chang et al 2006a; Lai et al 2006b; Shouval et al 2006).
(Chang et al 2006a). At week 48, histologic improvement 
(necroinﬂ  ammation score) occurred in signiﬁ  cantly higher 
proportion of patients treated with ETV compared to LAM 
(72% vs 62%, p = 0.009). Serum HBV DNA levels became 
undetectable by PCR methods in 67% and 36% (p   0.001) 
of the patients treated with ETV and LAM, respectively. 
Moreover, the mean reduction from baseline in the serum 
HBV DNA levels at week 48 was 6.9 log and 5.4 log in the 
ETV and LAM group respectively (p   0.001). Although 
ETV achieved a signiﬁ  cantly greater suppression of HBV 
DNA levels than LAM, the rate of HBeAg loss and HBeAg 
seroconversion did not differ signiﬁ  cantly between the two 
treatment groups being 22% and 21% in the ETV vs 20% and 
18% in the LAM arm (Chang et al 2006a, Table 1). At week 
48, 21% of the patient in the ETV group and 19% of those 
in the LAM group had achieved a complete response, 70% 
and 46% respectively had only virologic response and 5% 
and 26% respectively had no response. Among patients with 
response at week 48, 82% in the ETV and 73% in the LAM 
group sustained their response 24 weeks after discontinuation 
of treatment. There was no evidence of emergence of ETV 
resistant variants among 339 evaluated patients and although 
6 (2%) of ETV treated individuals experienced a virologic 
rebound during the ﬁ  rst year of therapy, samples obtained 
from these patients retained full phenotypic susceptibility to 
ETV . The adverse events were similar in the two groups. In 
the ETV group 3% of patients experienced alanine amino-
transferase ﬂ  ares (ALT levels more than twice the baseline 
level and more than 10 times the ULN) during treatment while 
such ﬂ  ares were observed in 6% of the patients in the LAM 
group. All ﬂ  ares in the ETV group were associated with a 
decline of HBV DNA levels by   2 log10 and all but one 
were self-limited with continuation of treatment, without any 
evidence of hepatic decompensation. On the other hand half of 
the ﬂ  ares in the LAM group were associated with increasing 
HBV DNA levels and in one patient hepatic decompensation 
developed. Post-treatment ALT ﬂ  ares were observed in 1% 
in the ETV group and in 7% of patients in the LAM group 
(Chang et al 2006a).
The efﬁ  cacy of extension of ETV and LAM treatment to 
week 96 in those HBeAg-positive patients who had only a 
virological response at week 48 without HBeAg seroconver-
sion, have also been evaluated (Gish et al 2005). During this 
period return of ALT to normal was achieved in 50% of the 
ETV and 42% of the LAM-treated patients. The cumulative 
virologic response rate at week 96 (Table 1), deﬁ  ned by HBV 
DNA  300copies/mL, was 80% in the ETV and 39% in the 
LAM group (p   0.001). Despite the signiﬁ  cantly greater 
suppression of HBV DNA in the ETV group, the cumula-
tive HBeAg seroconversion rate did not differ signiﬁ  cantly 
between the two treatment groups (Table 1) Furthermore, 
patients achieving only virologic response during the second 
year of therapy could receive double dose of ETV (1 mg) 
for at least one additional year. Thus 122 from 151 eligible 
HBeAg-positive patients were enrolled and evaluated at week 
144. Serum HBV DNA  300copies/mL and ALT normaliza-
tion were observed in 87% and 85% of patients respectively, 
while HBeAg loss and HBeAg seroconversion were achieved 
in 31% and 16% of them (Chang et al 2006b).
Efﬁ  cacy in HBeAg-negative patients
In a randomized double-blind trial, treatment with ETV 
0.5 mg was compared to LAM 100 mg once daily for at least 
52 weeks (Lai et al 2006b). According to the study protocol, 
similarly with the trial in HBeAg-positive patients, clinical-
management decisions were made at week 52 on the basis of 
the results of HBV DNA levels (b-DNA) and ALT levels on 
serum samples obtained at week 48. Response was deﬁ  ned as Therapeutics and Clinical Risk Management 2007:3(6) 1082
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undetectable serum HBV DNA ( 0.7Meq/mL by the b-DNA 
assay) and ALT levels below 1.25 times the upper limit of 
normal (ULN) and non response as a serum HBV DNA 
levels  0.7 Meq/mL. Treatment was discontinued at week 
52 both in responders and non-responders. Patients with only 
virologic response ( = undetectable serum HBV DNA levels 
 0.7 Meq/mL) and ALT levels  1.25xULN were offered 
continued therapy for up to 96 weeks. Histologic improve-
ment (reduction of necroinﬂ  ammation) occurred at week 48 
in signiﬁ  cantly more patients in the ETV than in the LAM 
group (70% vs 61%, p = 0.01). Undetectable serum HBV 
DNA levels by PCR and ALT normalization were observed 
in 90% and 78% and in 72% and 71% of patients treated with 
ETV and LAM, respectively (Lai et al 2006b). Eighty-ﬁ  ve 
percent of patients in the ETV group and 78%, (p = 0.04) in 
the LAM group had responded at week 48 while 10% and 
11% of each group had only virologic response. At the end 
of 24 weeks follow-up the response was sustained in 48% 
and 35% of the patients in the LAM and ETV group, respec-
tively. There was no evidence of ETV resistance at week 
48, in paired samples from 211 randomly selected patients 
in the ETV group but 5 (2%) of these patients experienced 
virologic rebound. Genotypic analysis from these patients 
revealed no emerging substitutions that confer resistance 
to ETV . Twenty-ﬁ  ve patients (8%) in the LAM group had 
a virologic rebound during the treatment period (Lai et al 
2006b). The adverse events between the two treatment groups 
were similar. Three patients in the ETV group experienced 
ALT ﬂ  ares, associated with a reduction of HBV DNA levels 
by at least 2 log10, that resolved spontaneously, while such 
ﬂ  ares occurred in 5 patients in the LAM group. In two of these 
5 patients alanine aminotransferase ﬂ  ares were associated 
with a reduction of HBV DNA levels by at least 2 log10 and 
in the other 3 with increasing HBV DNA levels. One of the 
last experienced the development of ascites. Post-treatment 
ALT ﬂ  ares occurred in 8% of the patients in the ETV and in 
11% in the LAM group (Lai et al 2006b).
Twenty-six patients in the ETV and 28 in the LAM group 
continued therapy up to week 96 (Shouval et al 2006). The 
cumulative virologic response through week 96 was 94% and 
77%, (p   0.0001) among ETV and LAM treated patients 
respectively, while biochemical response occurred in 89% 
and 84% of them (Shouval et al 2006).
In Table 1 the response rates at year 1 and 2 in HBeAg-
positive and HBeAg-negative patients treated by ETV or 
LAM are depicted. It is obvious that ETV is superior to 
LAM in terms of liver histology improvement, HBV DNA 
suppression, ALT normalization and the viral resistant 
strains development rate. Moreover despite the higher rate 
of HBV DNA suppression in ETV group the rate of HBeAg 
seroconversion was similar between the two groups for the 
treatment period.
Data from the above studies also indicated that response 
rate to ETV did not differ between patients with and without 
cirrhosis on liver biopsy (Schiff et al 2005). Although the 
number of cirrhotic patients was small in the two studies, 
histologic improvement occurred in a similar rate between 
patients with or without cirrhosis on liver biopsy at baseline, 
76% vs 72% in HBeAg-positive and 74% vs 70% in HBeAg-
negative patients, respectively (Schiff et al 2005).
Efﬁ  cacy of entecavir in patients with 
lamivudine- and adefovir-resistant 
HBV mutants
The efﬁ  cacy and safety of ETV in LAM-resistance patients 
were initially evaluated in a double-blind randomized 
dose-ranging trial. In this study, 182 patients with HBeAg- 
positive and -negative CHB and LAM-resistant HBV were 
enrolled and treated with 3 different daily doses of ETV 
(0.1 mg, 0.5 mg and 1 mg) in comparison to LAM 100 mg 
daily (Chang et al 2005). A signiﬁ  cant higher proportion of 
patients in the ETV 1 mg (79%) and 0.5 mg (51%) groups 
achieved serum HBV DNA levels   0.7 Meq/mL (by bDNA 
assay) compared to the LAM group (13%, p   0.0001), 
after 24 weeks of treatment (Chang et al 2005). Moreover 
the proportion of patients with undetectable serum HBV 
DNA by PCR assay was higher in ETV 1 mg (26%) and 
0.5 mg (26%) groups compared to LAM (4%, p   0.01) at 
48 weeks of treatment. HBeAg seroconversion was achieved 
in a minority of HBeAg-positive patients in all treatment 
groups (Chang et al 2005). The rate of biochemical remission 
at week 48 was superior in ETV 1 mg (68%) and 0.5 mg 
(59%) than in LAM (6%, p   0.001). In this study superiority 
of ETV at dose of 1 mg for the treatment of LAM-resistant 
patients was revealed. At baseline, 87% of the patients had 
lamivudine resistance-associated substitutions and at week 
48, 80% of them retained this substitution, regardless of treat-
ment group. Entecavir-associated resistance substitutions 
(rtT184, rtS202 and rtM250) were detected in 6 patients at 
baseline and emerged in 2 entecavir-treated patients (1 receiv-
ing 0.5 mg and 1 receiving 0.1 mg) during treatment period, 
but only one patient experienced viral rebound at week 48 
(Chang et al 2005). Viral rebound was also observed in 5 
ETV treated patients, but genotypic analysis could not reveal 
any entecavir-resistance mutations (Chang et al 2005).Therapeutics and Clinical Risk Management 2007:3(6) 1083
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In a randomized phase III trial, in HBeAg-positive CHB 
patients with LAM-resistant HBV , ETV 1 mg daily was 
compared with LAM 100 mg daily for at least 52 weeks 
(Sherman et al 2006). In this study clinical management 
decisions were again made at week 52, based on week 48 
results. Responders deﬁ  ned by serum HBV DNA levels   
0.7 Meq/mL by bDNA assay and HBeAg loss at week 48 and 
nonresponders (HBV DNA levels   0.7 Meq/mL) discontin-
ued treatment and followed-up for 24 weeks period. Patients 
with only virologic response at week 48 as deﬁ  ned by serum 
HBV DNA levels   0.7 Meq/mL by bDNA assay, without 
HBeAg loss, continued study medication until week 96 
(Sherman et al 2006). At week 48, histologic improvement 
observed in a higher proportion of patient in the ETV than in 
LAM group (55% vs 28%, p   0.001) (Table 2). Moreover 
the rates of virological response ( by PCR assay) and return 
of ALT to normal were higher in the ETV than in the LAM 
treated patients, 19% vs 1%, (p   0.0001) and 61% vs 15%, 
(p   0.0001), respectively. The rate of HBeAg seroconver-
sion did not differ between the two groups (ETV group 
8% and LAM group 3%, p = 0.06). At baseline 18 (6%) of 
lamivudine-refractory patients had substitutions that confer 
resistance to lamivudine and entecavir. Genotypic analysis 
of paired baseline and week 48 samples were performed for 
134 of the 141 ETV-treated patients and reveled 7 patients 
with mutations associated with ETV resistance at baseline. 
None of these patients exhibited virologic rebound during the 
ﬁ  rst year of therapy. Two other patients (1.4%) experienced 
a virologic rebound during ETV-treatment and genotypic 
analysis revealed mutations that confer resistance to ETV 
(Sherman et al 2006).
A number of patients in the ETV and the LAM groups 
continued treatment for a second year (Yurdaydin et al 2006). 
The cumulative conﬁ  rmed virologic, serologic (HBeAg 
seroconversion) and biochemical response at week 96 in 
the ETV and LAM groups were 30% and 1%, (p   0.0001), 
16% and 4%, (p = 0.0011) and 85% and 29%, (p   0.0001), 
respectively. Nine percent of the ETV treated patients exhib-
ited viral rebound due to ETV resistant mutations (Yurdaydin 
et al 2006).
After several years of use of adefovir dipivoxil, HBV 
resistance to this compound has been recognized among 
patients under long-term ADV monotherapy particularly after 
the second year of treatment with genotypic ADV resistance 
reaching 29% at year ﬁ  ve. In vitro studies have shown that 
ETV inhibits effectively the replication of ADV resistant 
HBV mutants (Brunelle et al 2005). However, clinical studies 
on the efﬁ  cacy of ETV in patients with ADV-resistant HBV 
mutants have not been performed yet, but in one recent report 
ETV treatment in two patients with ADV resistance showed 
a  3 log10 decline of HBV DNA levels after 6 months of 
therapy (Fung et al 2005).
Entecavir resistance
Entecavir resistance was ﬁ  rst been identiﬁ  ed in two patients 
with LAM-resistant strains, who experienced virologic 
breakthrough after more than 1 year of ETV therapy (Tenney 
et al 2004). Genotypic analysis of the polymerase region 
before the initiation of ETV treatment, had shown substitu-
tions conferring HBV resistance to LAM therapy: rtL180M, 
rtM204V , rtV173L in both patients. Genotypic analysis of the 
polymerase region after virologic breakthrough under ETV 
treatment showed that in addition to the LAM-resistance 
substitutions, the unique substitutions rtI169T (domain B) 
and rtM250V (domain E) in the ﬁ  rst patient and the rtS184G 
(domain B) and rtS202I (domain C) in the second one 
emerged (Tenney et al 2004). Phenotypic analysis of recom-
binant HBV genomes, containing patients’ RT domains or 
speciﬁ  c mutations, was performed. Substitution rtI169T 
alone or in combination with LAM-resistance substitutions 
did not decrease the susceptibility to ETV . Substitution 
rtM250V alone conferred a low level of ETV resistance, 
while in combination with LAM-resistance substitutions, 
a  1,000-fold reduction in ETV susceptibility was observed. 
Substitutions rtS184G and rtS202I alone did not confer resis-
tance to ETV , while either substitution in combination with 
LAM-resistance substitutions slightly reduced the suscepti-
bility to ETV . HBV containing all 4 substitutions rtL180M, 
rtM204V , rtS184G and rtS202I exhibited the highest level 
Table 2 Comparison of entecavir vs lamivudine in HBeAg 
positive lamivudine-resistance patients with chronic hepatitis B 
(CHB)
  Week 48    Week 96
 ETV  LAM  ETV  LAM
Undetectable 19%  1%  30%  1%
HBV DNA
ALT 61%  15%  85%  29%
Normal
HBeAg 8%  3%  16%  4%
seroconversion
Histologic   55%  28%  NA  NA
improvement
ETV 6%  NA  9%  NA
resistance
Abbreviations: ETV, entecavir; LAM, lamivudine; ALT, alanine aminotransferase;
NA, non applicable; vs, versus.
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of resistance ( 1,000-fold reduction in ETV susceptibility) 
(Tenney et al 2004). It is obvious that the pattern of ETV-
resistance is more complicated than LAM or ADV resistance 
because 3 or 4 substitutions in the polymerase region are 
required. Moreover, LAM-resistance substitutions are neces-
sary for the development of ETV resistant mutant. Until now 
three patterns of ETV resistance have been detected in LAM 
resistant strains: (1) substitutions rtI169T and rtM250V , 
(2) substitutions rtS184G and rtS202I and (3) substitutions 
rtS202G (Villet et al 2005).
In vitro studies have shown that ETV-resistant strains 
have no effect on the susceptibility to ADV . In 2 patients with 
ETV-resistance, ADV was administered in a dose of 10 mg 
daily with marked reduction in the viral load (Tenney et al 
2004). Thus, on clinical grounds ADV seems quite effec-
tive in patients with HBV mutants resistant to ETV and is 
probably the treatment of choice.
No evidence of resistance up to week 96 has been reported 
among ETV-treated nucleoside naïve patients (Gish et al 2005; 
Chang et al 2006a; Colonno et al 2006a; Lai et al 2006b; 
Shouval et al 2006). However, data from a recent study of 
3 years of ETV treatment have shown that the previous con-
cept of no-resistance in naive patients on ETV monotherapy 
is under question (Colonno et al 2006b). In this study, 
3 HBeAg-positive patients experienced a virologic breakthrough 
with genotypically conﬁ  rmed resistance in the third year of
treatment. Although this data, obtained under a complex study 
design, are compatible with a rate of resistance lower than 1% 
at the third year of treatment, this has to be conﬁ  rmed fol-
lowing a wide use of the drug in clinical practice (Figure 3). 
Moreover, while ETV genotypic resistance in LAM resistant 
mutants has been reported to be very low (6%) during the ﬁ  rst 
year of therapy increasing to approximately 14% at year two, 
new calculations on genotypic resistance have disclosed a 
cumulative rate of more than 30% at year 3 (Figure 3) (Colonno 
et al 2006b). Though a number of these patients may remain 
in low serum HBV-DNA levels, viral rebound increases from 
1% at the ﬁ  rst to 10% at the second and 25% at the third year 
of treatment. For the time being the rate of biochemical resis-
tance remains unknown because the deﬁ  nition of biochemical 
breakthrough (ALT   2x baseline or  10xULN) applied in 
this study (Colonno et al 2006b) actually refers to biochemical 
ﬂ  ares and not to biochemical breakthroughs which represent 
increase of normal ALT values to  1.25xULN.
As in the case of ETV therapy, patients with LAM-
resistant HBV mutants treated with Adefovir monotherapy 
Figure 3 The rate of Entecavir resistance in Naïve and Lamivudine-resistance chronic hepatitis B patients during 3 years of treatment.
Colonno RJ. AASLD 2006. Abstract 110.
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are also at signiﬁ  cantly higher risk to develop ADV resistant 
HBV mutants than LAM-naïve patients (Fung et al 2005, 
2006; Villet et al 2005; Yim et al 2006). On the other hand 
no patient with LAM-resistant strains treated by the com-
bination of ADV with LAM for up to 4 years, has hitherto 
developed ADV resistant HBV mutants (Lampertico et al 
2005; Rapti et al 2007). It is therefore reasonable to suggest 
that in patients with LAM-resistance HBV mutants sequential 
nucleos(t)ide monotherapy should be avoided and combina-
tion therapy be applied by 2 potent antiviral agents with 
different resistant proﬁ  les as is the case of combination of 
ETV with adefovir and preferable with tenofovir.
Conclusions
The high anti-HBV potency of entecavir, its impressive 
efﬁ  cacy in terms of rapid HBV suppression to undetectabil-
ity of HBV DNA by most sensitive PCR assays, combined 
with its high genetic barrier to HBV resistance, make ETV 
monotherapy a very attractive option as ﬁ  rst line treatment 
in lamivudine-naïve CHB patients both HBeAg-positive 
and HBeAg-negative. However, the hitherto duration of 
ETV phase III trials is short, their extension design com-
plex and appropriate long-term studies are needed before 
reaching deﬁ  nite conclusions on its very long-term safety 
and resistance.
In the setting of cirrhosis and liver transplantation, exist-
ing data are promising but limited.
In CHB patients with LAM-resistant HBV mutants, 
particularly those with advanced chronic liver disease, 
long term ETV monotherapy should be avoided, however 
this being true not only for ETV but for any sequential 
nucleos(t)ide analog monotherapy because of the increased 
risk for emergence of additional HBV resistance and 
multi-drug resistant HBV strains. In such setting the addi-
tion of adefovir or preferably tenofovir while continuing 
lamivudine, currently represents the treatment of choice 
but in the near future combination of ETV with ADV or 
tenofovir may turn out as the most preferable long term 
treatment strategy.
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